CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 276 enrolled
Drug / intervention
Calcium Carbonate +3 moredrug
Likely dose
Calcium Carbonate 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02186600
NCT02186600Phase 3Completed

Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women

University of Nebraska·interventional·Posted Jul 10, 2014·Updated Oct 5, 2023

In Brief

A Phase 3 clinical trial evaluating Calcium Carbonate, Vitamin D3, and 2 other interventions for Osteopenia. Completed, enrolled 276 participants across 1 site.

Detailed Summary

The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take calcium and vitamin D plus the medication "risedronate"; or 3) who take calcium and vitamin D plus participate in bone-loading exercises. Our central hypothesis is that improvements in bone health will be greater in women randomized to bone-loading exercises with calcium and vitamin D compared to women who take calcium and vitamin D only or women who take calcium and vitamin D plus risedronate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia
CountriesUnited States

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 10, 2014
Enrollment StartFeb 1, 2015
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.0 years ago

Interventions

Calcium Carbonatedrug

Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)

Vitamin D3drug

Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.

Risedronatedrug

Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.

Bone-loading exercisesbehavioral

Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.